The Lancet Gastroenterology & Hepatology in conversation with

Shahida Din and Beatriz Gros on the harms associated with receiving placebo in trials of drugs for inflammatory bowel disease

The Lancet Group

Shahida Din (Western General Hospital, Edinburgh) and Beatriz Gros (Reina Sofía University Hospital, Cordoba) discuss two new papers on the harms associated with receiving placebo in induction and maintenance trials of biological therapies and small molecules in inflammatory bowel disease.

Read the full articles:
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00264-4/fulltext?dgcid=buzzsprout_icw_podcast_generic_langas
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00233-4/fulltext?dgcid=buzzsprout_icw_podcast_generic_langas

Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv